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Oral cancer in patients with mental retardation has not been reported in detail, although the literature on clinical
management of oral malignancies in the general population is extensive. No clear consensus has been established
regarding the management of oral cancer in patients with mental retardation. We present herein the case of a
32-year-old Japanese man with mental retardation due to microcephaly who presented with advanced tongue
cancer. He was treated with three courses of chemotherapy using superselective intra-arterial infusion of cisplatin at
100 mg/m2 via the femoral artery (Seldinger method). No major complications were encountered, and complete
response was achieved. The patient has shown no clinical or radiological evidence of local recurrence or distant
metastases as of 22 months after the end of treatment. This case provides a basis for the future appropriate management
of oral cancer in patients with mental retardation.
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The literature on the clinical management of oral ma-
lignancies in the general population is extensive. Diag-
nosis and management planning for the staging of
patients with squamous cell carcinoma (SCC) of the
head and neck region has increasingly been reported.
However, issues associated with oral cancer in patients
with mental retardation have not been widely dis-
cussed, since the importance of environmental and
constitutional risk factors associated with mental re-
tardation are unclear. Due to the difficulties in com-
municating about their own oral health, achieving the
cooperation of the patient with the treatment proced-
ure is always complicated. In addition, poor ability in
communication can delay the diagnosis of oral cancer.
To improve the lack of information on oral cancer in
patients with mental retardation, further reports are
required. We present a case of tongue cancer in a pa-
tient with mental retardation due to microcephaly.
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A 32-year-old Japanese man was referred with his par-
ents to our clinic in August 2012 complaining of
swelling of the left tongue. Considerable swelling in
the left tongue was evident (Fig. 1a), but no lymph
nodes were palpable on the either side of the neck.
The patient had mental retardation due to microceph-
aly, and needed supportive care for all activities of
daily living. Magnetic resonance imaging (MRI) and
contrast-enhanced computed tomography (CT) were
performed with intravenous sedation. On MRI, hyper-
intensity on short T1 inversion recovery (STIR) im-
ages and contrast-enhanced T1-weighted images
(maximum length 42 mm) was observed in the left
tongue (Fig. 2a, b). CT evaluation of the tongue was
unclear due to a metal artifact caused by a dental
prosthesis. Biopsy of the left tongue lesion was per-
formed under intravenous sedation, revealing well-
differentiated SCC. Finally, a diagnosis of SCC of the
left tongue with no lymph node metastasis was estab-
lished. The tumor was staged as T3N0M0 (stage III)
according to the Union for International Cancer Con-
trol staging system.
After sufficient consultation with an interdisciplin-
ary team and provision of informed consent by hisarticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Intraoral findings. Intraoral photographs at initial presentation
(a) and at 22 months after treatment (b). Advanced cancer is seen in
the left lateral tongue with marked swelling
Fig. 2 MRI assessment at initial examination. STIR (a) and
contrast-enhanced T1-weighted imaging (b) on initial presentation show
a prominent hyperintense lesion in the left tongue
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strategy. Three courses of chemotherapy were admin-
istered using superselective intra-arterial infusion via the
femoral artery (Seldinger method) with cisplatin (CDDP) at
100 mg/m2. The interval for chemotherapy was set at
2 weeks. During chemotherapy, the patient developed grade
1 stomatitis, grade 1 vomiting, and grade 2 neutropenia
(National Cancer Institute common toxicity criteria, ver-
sion 3.0). MRI assessment obtained 2 weeks after com-
pleting the treatment course demonstrated dramatic
regression of the tumor. After 22 months, the treat-
ment was deemed to have achieved complete response
(CR) (Figs. 1b and 3a, b).
This represents the first description of advanced
tongue cancer in a patient with mental retardation
treated with chemotherapy using superselective intra-
arterial infusion by the Seldinger method.The incidence of cancer in individuals with mental re-
tardation is reportedly as frequent as in the general
population, although the frequency of oral cancer with
mental retardation may be slightly reduced because of
reduced exposures to risk factors for oral SCC such as
tobacco and alcohol [1–5]. However, treatment strategies
for oral cancer in patients with mental retardation are
unclear, with only a few studies reported [1, 6]. As far as
we have been able to determine from a PubMed search
Fig. 3 MRI assessment after treatment. STIR (a) and contrast-
enhanced T1-weighted imaging (b) at 22 months after treatment
show no apparent abnormal lesion in the corresponding area
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tongue cancer among individuals with mental retardation
have been reported, including the present case [6–12]. The
prognosis for these cancer patients seems unfavorable
(Table 1). In addition, information on the treatment process
is lacking, with descriptions in only a small number of re-
ports. Further information is thus required.
One of the major factors is that treatment for oral
cancer in patients with mental retardation is difficultdue to the impaired physiological situation based on
the biological background, as well as difficulties with
understanding and communication. In addition, the
poor ability of these patients in communicating about
their own health situation may delay the diagnosis of
oral cancer, as evidenced by the delayed discovery and
diagnosis of advanced tongue cancer in the present
case. Generally, a high survival rate cannot be expected
with advanced oral cancer (stage III or IV), unlike
stage I or II oral cancer. Surgery and postoperative
radiotherapy and/or chemotherapy are thus suggested
as standard treatments. These treatments, however,
have major side effects such as impaired swallowing
and pronunciation problems due to the resulting
physiological changes, or the development of oral sto-
matitis. Considering the standard treatment of oral
cancer, particularly for tongue cancer, impaired swal-
lowing ability or postoperative tracheal anomalies
resulting from surgery are unacceptable for patients
with mental retardation [1]. Surgery or anesthesia will
occasionally be inadequate because of biological con-
ditions such as atlantoaxial instability or cardiomyop-
athy. Daily treatments requiring the body to be kept
still for long periods in radiotherapy may be difficult,
and predictable development of oral stomatitis can be
intolerable for patients with tongue cancer. Chemo-
therapy also needs modification of the protocol, in accord-
ance with the biochemical and metabolic condition of
the patient. In these regards, chemotherapy could be
adapted to patients with mental retardation, as previ-
ously reported [1]. The efficacy and advantages of
superselective intra-arterial chemotherapy for head
and neck cancer have recently been reported in several
papers [13–17], and infusion using the Seldinger
method proved adequate in the present case. Chemo-
therapy with CDDP on day 1 using the Seldinger
method was thought to be suitable for this patient,
while daily concurrent chemotherapy with infusion via
a superficial temporal artery may have been unaccept-
able and difficult. In this patient, three courses of
chemotherapy were administered, each under general
anesthesia. Since general anesthesia is often needed
for dental treatments in patients with mental retard-
ation due to their difficulty in communicating with
medical staff, general anesthesia appeared reasonable
in the present case.
After 22 months, the treatment was deemed to have
achieved CR, although further observation is required.
Chemotherapy using superselective intra-arterial infu-
sion by the Seldinger method with CDDP was therefore
effective as treatment for the present patient.
The treatment strategy for oral cancer in patients with
mental retardation is difficult and poorly known in many
aspects. A multidisciplinary approach should thus be
Table 1 Review of the literature: 11 cases of tongue cancers in patients with mental retardation
Authors’ prognosis Sex/age Associated disease TNM Treatment Follow-up term
Jancar et al. [10] NA F/60 Cockayne syndrome NA NA NA
Farhat et al. [8] DOD M/27 Down syndrome T2N0M0 S/CRT 1 year
Sund et al. [6] NA F/54 Fragile X syndrome NA NA NA
Kiani et al. [11] DOD F/NA NA NA NA NA
Hennequin et al. [9] NA Down syndrome NA NA NA
DOD
DOD NA Down syndrome NA NA NA
Satge et al. [5] DOD F/NA NA NA NA NA
Butt et al. [7] NA M/17 XP NA NA NA
Alive at 21 years M/20 XP NA S 1 year
NA M/11 XP T1NxM1 S 6 months
Enomoto et al. Alive at 34 years M/32 Microcephaly T3N0M0 CT 2 years
TNM TNM classification, NA not available, DOD dead of disease, XP xeroderma pigmentosa, S surgery, CRT chemoradiotherapy, CT chemotherapy
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lated and shared.
Conclusions
We present the case of mental retardation patient with
advanced tongue cancer. The three courses of chemo-
therapy using superselective intra-arterial infusion of cis-
platin via the femoral artery (Seldinger method) were
performed. The patient has shown no clinical or radio-
logical evidence of local recurrence or distant metastases
as of 22 months after the end of treatment.
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